Clinical Trials Directory

Trials / Conditions / Inflammatory Myopathy

Inflammatory Myopathy

25 registered clinical trials studyying Inflammatory Myopathy — 18 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingUCAR T-cell Therapy Targeting CD19/ BCMA(QT-019C) in Patients With Relapse/ Refractory Autoimmune Diseases
NCT07410377
The Affiliated Hospital of Xuzhou Medical UniversityEARLY_Phase 1
Not Yet RecruitingTELITACICEPT IN INFLAMMATORY MYOPATHIES(TELITACICEPT-IM)
NCT07355257
Zhongming QiuPhase 2 / Phase 3
RecruitingA Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases
NCT07413341
TherornaPhase 1
RecruitingAn Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
NCT07236762
China Immunotech (Beijing) Biotechnology Co., Ltd.Phase 1
RecruitingExploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases
NCT07236801
China Immunotech (Beijing) Biotechnology Co., Ltd.Phase 1
RecruitingA Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
NCT07123519
China Immunotech (Beijing) Biotechnology Co., Ltd.Phase 1
RecruitingA Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
NCT07104721
China Immunotech (Beijing) Biotechnology Co., Ltd.Phase 1
RecruitingMIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)
NCT07374107
Myositis International Health & Research Collaborative Alliance Foundation—
RecruitingA Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
NCT06978647
China Immunotech (Beijing) Biotechnology Co., Ltd.Phase 1
Not Yet RecruitingUCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
NCT06978738
Changzhou No.2 People's HospitalPhase 1
RecruitingCAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
NCT06941129
Institute of Hematology & Blood Diseases Hospital, ChinaPhase 1
CompletedVirtual Reality and Robotics in Inflammatory Myopathy Rehabilitation
NCT06968819
National Institute of Geriatrics, Rheumatology and Rehabilitation, PolandN/A
RecruitingBCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
NCT06794008
Peking University People's HospitalPhase 2
Not Yet RecruitingThe Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases
NCT06420154
First Affiliated Hospital of Wenzhou Medical UniversityEARLY_Phase 1
RecruitingAn Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease
NCT06379646
China Immunotech (Beijing) Biotechnology Co., Ltd.N/A
RecruitingAnti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease
NCT06373081
Shanghai Changzheng HospitalN/A
RecruitingRenal Manifestations During Idiopathic Inflammatory Myopathies
NCT06904937
University Hospital, Strasbourg, France—
Not Yet RecruitingAdult Idiopathic Inflammatory Myopathy With Cardiac Injury
NCT05982041
The First Affiliated Hospital with Nanjing Medical University—
Enrolling By InvitationUniversal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases
NCT05859997
Bioray LaboratoriesN/A
UnknownSerologic Profile of SARS CoV2 in COVID-19 Patients With Systemic Diseases
NCT04530461
faida agili—
UnknownLow-dose Interleukin-2 in Combination With Standard Therapy on Idiopathic Inflammatory Myopathy
NCT04237987
Peking University People's HospitalPhase 2
UnknownLow-dose Interleukin-2 Treatment on Idiopathic Inflammatory Myopathy
NCT04062019
Peking University People's HospitalPhase 2
CompletedYellow Fever Vaccine in Patients With Rheumatic Diseases
NCT03430388
University of Sao Paulo General HospitalN/A
CompletedQuantitative Muscle Ultrasound as a Marker of Progression in Children With Muscular Diseases
NCT03786913
Benha University—
UnknownPersonalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation
NCT04687111
Mark LedwidgePhase 2